🔗 Share this article Users Coming Off Anti-Obesity Jabs Put On Pounds Far More Rapidly Compared to People Using Diet and Exercise Weight management involves long-term strategies. A recent study suggests that people who come off new weight-loss injections like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise plans. Findings released in a major medical journal demonstrates that while overweight people often shed a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation. "Individuals purchasing these medications must be informed of the danger of rapid weight regain when the therapy concludes," stated researcher Dr. Susan Jebb. This pace of regain implies a return to starting mass in about 18 months. Analyzing Approaches The analysis, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting. Researchers note that individuals who lose weight through diet and exercise generally experience a less rapid creep back—around 0.1 kg a month—once they finish. Understanding the Rapid Regain Experts believe the mechanism of the drugs is key to understanding the amplified rebound. The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist. "Discontinuation of this medication means appetite is unsuppressed, making binge eating a significant risk." A Chronic Condition? The NHS advise the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes. A number of clinicians argue that, given the high risk of weight regain, the treatment might need to be ongoing. This view is supported by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," akin to managing conditions like hypertension. Patient Testimonies Individuals who have stopped the jabs explain a intense resurgence of appetite. "It was like a switch flipping and you're instantly ravenous," said a patient. This difficulty is compounded if patients have not established permanent dietary or behavioural modifications during treatment. Significant Use Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high. Use is greater among females compared to men. The middle-aged demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle support.
Weight management involves long-term strategies. A recent study suggests that people who come off new weight-loss injections like Wegovy and Mounjaro tend to recover shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise plans. Findings released in a major medical journal demonstrates that while overweight people often shed a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation. "Individuals purchasing these medications must be informed of the danger of rapid weight regain when the therapy concludes," stated researcher Dr. Susan Jebb. This pace of regain implies a return to starting mass in about 18 months. Analyzing Approaches The analysis, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of the injectable medications with conventional dieting. Researchers note that individuals who lose weight through diet and exercise generally experience a less rapid creep back—around 0.1 kg a month—once they finish. Understanding the Rapid Regain Experts believe the mechanism of the drugs is key to understanding the amplified rebound. The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist. "Discontinuation of this medication means appetite is unsuppressed, making binge eating a significant risk." A Chronic Condition? The NHS advise the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes. A number of clinicians argue that, given the high risk of weight regain, the treatment might need to be ongoing. This view is supported by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," akin to managing conditions like hypertension. Patient Testimonies Individuals who have stopped the jabs explain a intense resurgence of appetite. "It was like a switch flipping and you're instantly ravenous," said a patient. This difficulty is compounded if patients have not established permanent dietary or behavioural modifications during treatment. Significant Use Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with interest remaining high. Use is greater among females compared to men. The middle-aged demographic shows the greatest level of interest. A large proportion obtain the drugs through private prescriptions rather than public health services. Finally, experts caution that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent cure and lasting health benefits relies on ongoing lifestyle support.